Vimta Labs Limited , a leading contract research and testing organization, has reported its highest ever quarterly revenue of INR 993.00 million for Q1 FY2026, marking a significant 31.4% year-on-year growth from INR 756.00 million in the same quarter last year.

Financial Highlights

Operational Highlights

• Successfully completed an unannounced US FDA GCP inspection with no Form 483 observations
• Received cGMP compliance letter from ANSM EMA
• Board approved a 1:1 bonus issue
• Completed facility expansion of 200,000 square feet to support future growth
• Maintains a debt-free balance sheet with cash equivalents of INR 379.30 million

Business Segment Performance

Future Outlook

Vimta Labs is progressing with equipment procurement for biologics contract research services, expected to commercialize from Q1 FY2027. The company's expanded facility and strategic investments position it well for future growth across all service offerings.

Ms. Harita Vasireddi, Managing Director of Vimta Labs, commented, "We are pleased to report our highest ever quarterly revenue, putting us on a very strong growth trajectory. The market shifts, emergence of new technologies, and continuous innovation in the pharmaceutical and nutraceutical sectors have significantly heightened the focus on product quality and safety, an area where Vimta is distinctly well positioned."

With its strong financial position, ongoing investments in capacity expansion, and focus on quality and scientific precision, Vimta Labs appears well-positioned to capitalize on the growing demand for contract research and testing services in the pharmaceutical, food, and electronics sectors.

Note: All financial figures are in Indian Rupees (INR).

Vimta Labs , a leading testing and research organization, has announced its financial results for the first quarter, showcasing robust growth in profit, revenue, and EBITDA.

Strong Profit Growth

Vimta Labs reported a significant increase in its net profit for Q1, which rose to ₹189.00 crore from ₹140.00 crore in the same quarter of the previous year. This represents a substantial year-over-year growth of 35%, indicating improved profitability for the company.

Impressive Revenue Performance

The company's revenue also demonstrated strong performance in Q1, climbing to ₹976.00 crore from ₹747.00 crore in the corresponding quarter last year. This 31% year-over-year increase in revenue suggests a notable expansion in Vimta Labs' business operations and market presence.

EBITDA Growth

Vimta Labs has reported a Q1 EBITDA of ₹337.00 crore, compared to ₹259.00 crore in the same quarter last year, showing a significant year-over-year increase of 30%. The company's Q1 EBITDA margin was 34.53%, slightly lower than the 34.63% reported in the corresponding quarter of the previous year.

Financial Highlights

To better illustrate Vimta Labs' Q1 performance, here's a summary of the key financial metrics:

The substantial growth in net profit, revenue, and EBITDA indicates that Vimta Labs has successfully expanded its operations while maintaining efficient cost management. This performance suggests a positive trajectory for the company in the current fiscal year.

While specific factors contributing to this growth were not detailed in the quarterly report, the significant increase in financial metrics may be attributed to factors such as increased demand for testing services, expansion of service offerings, or improved operational efficiencies.

Investors and market analysts are likely to view these results favorably, as they demonstrate Vimta Labs' ability to grow its business and improve profitability in the current economic environment.